Concerns Addressed: Ixekizumab and Inflammatory Bowel Disease

Overview of Ixekizumab and Its Application

Ixekizumab, an antibody currently approved for plaque psoriasis treatment, targets a cytokine potentially involved in the pathogenesis of inflammatory bowel disease (IBD). This connection has raised concerns regarding the possibility of ixekizumab increasing the incidence of IBD in psoriasis patients.

Recent Study Findings

A recent study published in the American Journal of Dermatology has alleviated these concerns. Plaque psoriasis is characterized by raised, red scales that can be itchy and painful. Notably, there is a significant genetic overlap between psoriasis and IBD, leading to co-morbidities where patients may develop IBD alongside psoriasis.

Understanding Inflammatory Bowel Disease

IBD primarily manifests as Crohn’s disease or ulcerative colitis, both conditions marked by chronic and recurrent intestinal inflammation. Previous animal and human studies have indicated a potential role of the cytokine interleukin-17 (IL-17) in IBD’s development, although findings have often been inconsistent. Clinical trials involving IL-17A antagonists have not shown effectiveness in treating Crohn’s disease and, in some cases, have resulted in worsened patient outcomes.

Study Conducted by Eli Lilly and Company

Recognizing the genetic similarities between psoriasis and IBD, Eli Lilly and Company, the developer of ixekizumab, initiated a study to investigate the incidence of IBD in psoriasis patients receiving this treatment. An independent external committee was established to analyze data from 4,029 patients with moderate to severe psoriasis who had been treated with ixekizumab. These participants were drawn from seven different randomized clinical trials.

Adjudication Process

IBD adjudication was conducted using an internationally recognized classification system that involved comprehensive reviews of radiographic, endoscopic, pathological, clinical, and laboratory features.

Conclusion of the Study

The findings published in the American Journal of Dermatology revealed that the occurrence of new IBD cases, encompassing both Crohn’s disease and ulcerative colitis, was infrequent among patients treated with ixekizumab.